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Background: In recent years, non-motor features of Parkinson's disease (PD) have received increasing
attention and PD is currently considered a systemic rather than a pure basal ganglia disorder. Among the
systemic features, peripheral neuropathy (PN) is a recent acquisition since the ﬁrst caseecontrol study
reporting increased frequency of PN in PD dates back to 2008.
Methods: We reviewed available literature on peripheral nervous system (PNS) involvement in PD.
Results: Evidence of a-synuclein deposition in the PNS and small nerve ﬁber deterioration in both drug-
naïve and treated PD patients is becoming stronger. In addition, several recent reports documented a
signiﬁcant role of levodopa exposure together with group B vitamin deﬁciency in facilitating the devel-
opment of PN and case reports suggested that treatmentwith continuous levodopa intestinal infusionmay
increase the risk of acute PN compared to both oral levodopa and other dopaminergic treatments.
Conclusion: It is currently debated whether PN is an intrinsic disease-related feature, a consequence of
levodopa treatment or both. In this review, we will discuss the different hypotheses, as well as our
perspective on open issues and controversies.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
1.1. Parkinson's disease: a systemic disease
Parkinson's disease (PD) is the second most frequent neurode-
generative disorder, and is clinically deﬁned by the presence ofal Medicine, Amedeo Avoga-
l.: þ39 0321 3733965.
Ltd. This is an open access article uresting tremor, rigidity and bradykinesia [1]. These features are
collectively referred to as motor symptoms and mostly correlated
to loss of dopaminergic neurons in the pars compacta of midbrain
substantia nigra. The histological hallmark of the disease is the
presence in the surviving neurons of intracytoplasmic inclusions
known as Lewy bodies, mainly composed by a-synuclein aggre-
gates. a-synuclein exerts multiple functions in health and disease,
and its role in PD is not fully deﬁned yet. It is believed that the
accumulation of this protein may exert a detrimental effect on
survived neurons, partly due to the activation of pro-inﬂammatorynder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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uclein deposits may impair axonal transport [4].
The traditional view of PD as a basal ganglia disorder is coun-
terbalanced by strong clinical and neuropathological evidence of
systemic involvement. Indeed, PD patients present a wide range of
non-motor features, including anosmia, sleep disturbances, con-
stipation, mood deﬂection and pain, and their onset can even
precede motor impairment [5]. Lewy bodies are not exclusively
present in the basal ganglia, but can be detected, sometimes before
clinical diagnosis, in several other nervous structures such as the
olfactory cortex, brainstem nuclei, and enteric, pelvic and cardiac
ganglia [6]. Furthermore, a-synuclein was shown to be highly
expressed in the skin of PD patients, namely in the spinous cell
layer, pilosebaceous unit, and eccrine glands, whereas it is scarcely
expressed in atypical PD, and absent in controls [7].
Since the peripheral nervous system (PNS) is a target of a-syn-
uclein deposition, there is growing interest in assessing whether
the intrinsic pathogenetic features of PD may predispose to pe-
ripheral neuropathy (PN). In fact, several recent reports have
documented increased frequency of PN in PD patients compared to
age-matched healthy subjects. Most studies included patients un-
dergoing pharmacological treatment and correlations with levo-
dopa (LD) exposure and alterations in vitamin B12 (VB12)
metabolism were found in independent reports, thus rising the
question onwhether PN is an additional systemic feature of PD, or a
side effect of pharmacological treatment.
In the following sections we will review the evidence in both
directions, and discuss which controversies are still to be
unraveled.
2. Parkinson's disease is a determinant of neuropathy
Evidence of pathological changes in the PNS of PD patients is
rapidly accumulating. a-synuclein aggregates have been detected
in the pharyngeal motor and sensory branch of vagus nerve, in the
glossopharyngeal nerve and in the internal superior laryngeal
nerve in PD patients with dysphagia [8,9]. Lewy bodies have also
been found in the dorsal vagus ganglion and parasympathetic
sacral nuclei, as well as in the enteric nervous system, and cardiacTable 1
Studies investigating intrinsic PNS damage in PD.
Authors Study population Number an
Nolano et al. (2008) [16] 48 subjects (18 PD, 30 controls) 18/18 (100
of controls
Ikemura et al. (2008) [19] 279 patients (85 PD, 194 patients
without CNS LB pathology)
20/85 (24%
of patients
Miki et al. (2010) [17] 20 PD patients, no control group 2/20 (10%)
Nolano et al. (2011) [18] 3 PD patients, and re-assessment of the
previous study population. No new
control subjects
3/3 (100%)
Wang et al. (2013) [20] 34 subjects (20 PD, 14 controls) 20/20 (100
of controls
Donadio et al. (2014) [21] 71 subjects (21 PD, treated and untreated,
20 patients with other parkinsonian
syndromes, 30 controls).
21/21 (100
of patients
syndromes
Doppler et al. (2014) [22] 66 subjects (31 PD, 35 controls) 16/31 (52%
of controls
Abbreviations: CNS ¼ central nervous system; ENF ¼ epidermal nerve ﬁbers; ENG ¼ elec
PD ¼ Parkinson's disease; PM ¼ pilomotor; SM ¼ sudomotor.and pelvic plexus, even in early disease stages [10e14]. Further-
more, experimental evidence from animal models suggests that a-
synuclein may be involved in axonal degeneration following trau-
matic peripheral nerve injury [15]. Both cutaneous ﬁbers abnor-
malities and a-synuclein deposition have been detected. One report
showed that PD patients display loss of epidermal nerve ﬁbers and
Meissner corpuscles, clinically correlated to sensory dysfunction
[16] (Table 1). Moreover, presence of a-synuclein aggregates in
unmyelinated ﬁbers of the dermis, and distal sensory and auto-
nomic neuropathy have been reported in PD as well as other Lewy
body diseases [17] (Table 1). Notably, a-synuclein deposition was
detected in pilomotor and sudomotor but not in sensory nerves
[18e20] (Table 1). Intriguingly, cutaneous abnormalities may be
detected also in recently diagnosed/untreated PD patients and a-
synuclein ratio, i.e. a-synuclein deposition normalized to nerve ﬁ-
ber density, positively correlates with Hohen & Yahr stage, sug-
gesting that PNS involvement is a primary expression of PD instead
of a consequence of its treatment and that it evolves with disease
progression [20] (Table 1). Accordingly, Donadio et al. recently
detected phosphorylated a-synuclein deposition and small nerve
ﬁber neuropathy in PD patients. Both ﬁndings were not present in
healthy controls and in patients with other parkinsonian syn-
dromes such as vascular parkinsonism, tauopathies and Parkin
mutation carriers. Furthermore, no differences in disease duration,
LD exposure and risk factors for neuropathy, including VB12 deﬁ-
ciency, were found in idiopathic PD compared to other parkinso-
nian syndromes [21] (Table 1). Similar results were recently
reported by Doppler et al. who detected a signiﬁcant difference in
both phosphorylated a-synuclein deposition and loss of small
nerve ﬁbers between idiopathic PD patients and controls. Also, in
this study the authors did not ﬁnd a correlation between patho-
logical ﬁndings and both cumulative LD intake and markers of LD
toxicity and suggested that phosphorylated a-synuclein dermal
deposition may be a diagnostic marker of PD, even though with a
relatively low sensitivity [22] (Table 1). Phosphorylated a-synuclein
deposition seems more typical of small nerve ﬁbers. Indeed, a
recent neuropathological study on superﬁcial peroneal nerve bi-
opsies in patients with axonal neuropathy identiﬁed increased
frequency of intra-axonal ubiquitin and 14-3-3 b but not ofd percentage of reported cases Main ﬁndings
%) of PD patients, 0/30 (0%) Signiﬁcant reduction of ENF and MC in PD.
Normal ENG ﬁndings.
) of PD patients, 0/194 (0%)
without CNS LB.
Anti-phosphorylated alpha-synuclein
immunoreactivity in skin from the abdominal
wall and upper arm.
of PD patients. Anti-phosphorylated alpha-synuclein
immunoreactivity in the skin form chest
wall and leg.
of PD patients. Loss of ENF in both treated and untreated
patients. Loss of MC only in treated patients
%) of PD patients, 0/14 (0%) Signiﬁcant loss of IE and PM ﬁbers, and
morphologic changes to SM ﬁbers in PD
compared to controls. Greater a-synuclein
deposition and higher a-synuclein ratios in
PD compared to controls within PM
and SM nerves
%) of PD patients, 0/50 (0%)
with other parkinsonian
and controls
Anti-phosphorylated alpha-synuclein
immunoreactivity in the skin form proximal
and distal sites.
) of PD patients, 0/35 (0%) Anti-phosphorylated alpha-synuclein
immunoreactivity in the skin from proximal
and distal leg, back and index ﬁnger.
troneurography; IE ¼ intraepidermal; LB ¼ Lewy bodies; MC ¼Meissner corpuscles;
Table 2
Studies investigating extrinsic determinants of PN in PD.
Authors Study population Number and percentage of reported cases Main ﬁndings
ORAL LEVODOPA
Müller et al. (2004) [30] 58 subjects (31 PD and 27 controls) 20/31 (64%) of PD patients, 0/27 of controls Axonal sensory PN in PD patients.
Correlation with high levels of Hcy
Toth et al. (2008) [27] 758 subjects (550 PD and 258 non-PD
PN patients)
49/500 (9.8%) of PD patients, 34 of whom
(6.4%) had idiopathic PN
Axonal PN. 3 patients had a CIDP-like
pattern. 32/34 patients had elevated Hcy
and MMA levels and decreased folate and
VB12 levels
Toth et al. (2010) [26] 116 patients (58 PD patients and
58 controls)
32/58 (55%) of PD patients, 5/58 (9%) of
controls.
Axonal predominantly sensory PN.
Higher levels of MMA and Hcy in PD
patients compared to controls
Gondim et al. (2010) [44] 10 PD patients, no control group 10/10 (100%) of PD patients. Axonal sensory-motor PN
Rajabally et al. (2011) [28] 74 subjects (37 PD patients and
37 controls)
14/37 (37.8%) of PD patients, 3/37 (8.1%) of
controls
Axonal PN.
Correlation with VB12 deﬁciency
Kimber et al. (2013) [45] 4 PD patients, no control group 4/4 (100%) of PD patients. Primary axonal pattern with secondary
demyelination
Ceravolo et al. (2013) [25] 467 subjects (330 PD patients:
144 LELD, 103 SELD,83 NOLD
and 137 controls)
28/144 (19.40%) of LELD PD, 7/103 (6.80%)
of SELD PD; 4/83 (4.82%) of NOLD PD
patients and 12/137 (8.76%) of controls
Axonal predominantly sensory PN.
Age and duration of exposure to LD are best
predictors of PN.
Lower VB12, higher Hcy and LD dose in PD
with PN versus non PN subjects
CONTINUOUS LEVODOPA INTESTINAL INFUSION
Antonini et al. (2007) [49] 9 PD patients, no control group 9/9 (100%) of PD patients. Acute or subacute axonal PN
Manca et al. (2009) [50] Single case report, no control group 1/1 (100%) of PD patients. Acute axonal PN
Urban et al. (2010) [42] 2 PD patients, no control group 2/2 (100%) of PD patients Mild axonal sensory-motor PN
Santos-Garcìa et al. (2011) [43] 5 PD patients, no control group 1/5 (20%) of PD patients. Subacute generalized axonal sensory-motor
PN
Meppelink et al. (2011) [51] 15 PD patients, no control group 2/15 (13%) of PD patients. Axonal sensory PN
Klostermann et al. (2012) [53] 2 PD patients, no control group 2/2 (100%) of PD patients. Subacute axonal PN
Galazky et al. (2013) [46] 2 PD patients, no control group 2/2 (100%) of PD patients. Mixed axonal- demyelinating PN after 4 and
13 months of CLDII, with CSF albumin-
cytologic dissociation
Jugel et al. (2013) [48] 30 PD patients (15 on O-LD and
15 on CLDII)
15/15 (%) of O-LD patients, 15/15 (%) of
CLDII patients
Axonal PN in both groups, with a more
severe presentation in CLDII patients
Merola et al. (2014) [43] 15 PD patients, 10 with follow-up,
no control group
3/15 (20%) of PD patients at baseline. After 9
months follow-up 1/10 (10%) of patients
developed PN, 3/10 (30%) of patients had a
worsening of pre-existing PN
Subacute sensory-motor axonal neuropathy
Mancini et al. (2014) [35] 150 PD patients (50 on ODT 50 on
O-LD 50 on CLDII), no control group
3/50 (6%) of ODT, 10/50 (20%) of O-LD, 14/
50 (28%) of CLDII patients
Axonal PN in % cases; acute (GBS-like) PN in
% of CLDII
Abbreviations: CIDP¼ chronic inﬂammatory demyelinating polyneuropathy; CLDII¼ continuous levodopa intestinal infusion; CSF¼ cerebrospinal ﬂuid; GBS¼ Guillain-Barre
syndrome; Hcy ¼ Homocysteine; LELD ¼ long exposure to levodopa; MMA ¼ Methylmalonic acid; NOLD ¼ no exposure to levodopa; O-LD ¼ oral levodopa; ODT ¼ other
dopaminergic therapy; PD ¼ Parkinson's disease; PN ¼ Peripheral neuropathy; SELD ¼ short exposure to levodopa; VB12 ¼ vitamin B12.
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compared to other patients with axonal neuropathy [23].
Finally, Vitale et al. detected peripheral sensorineural hearing
loss in PD patients compared to matched healthy controls. Since no
causal relationship with LD therapy was found, authors suggested
that such sensory impairment may be an intrinsic PD feature [24].
3. Levodopa exposure is a determinant of neuropathy
Studies investigating the frequency of PN in PD patients on LD
therapy, detected a signiﬁcant increase compared to age-matched
healthy subjects, although the reported data range varied from
4.8% [25] to 55% [26] (Table 2). This wide discrepancy is probably
due to intrinsic differences of the study population in terms of age,
disease duration and therapeutic regimen, as well as of the meth-
odology used to detect PN: i) clinical signs only versus neuro-
physiological data, ii) diagnostic criteria used for diagnosis.
Nonetheless, a correlation between PN development and both total
LD dose and exposure to LD over time was observed [25e28].
Regarding the possible pathogenetic link between LD and PN, it
has been suggested that LD could favor nerve damage by inter-
acting with the homocysteine (hcy)/VB12 cycle.
Conversion of LD to dopamine requires a methyl group dona-
tion that is provided by adenosylmethionine, and such reaction
leads to hcy formation. Subsequent hcy re-methylation requiresVB12 as co-factor, and alternative ways of degradation require
methylentetrahydrofolate and piridoxine (vitamin B6). Therefore,
chronic LD use leads to methyl-group depletion and hcy over-
production. The ﬁnal result is that chronic LD intake leads to hcy
accumulation and vitamin B6, VB12 and folate depletion. Inter-
estingly, inhibition of catechol-O-methyltransferase (COMT),
which is an effective pharmacological approach to prolong LD
effect in advanced PD patients, was shown to decrease hcy levels
in LD treated PD patients [29].
PN may be part of a more complex clinical picture related to
VB12 deﬁciency and a concurrent contribution to PNS damage by
hyperhomocysteinemia has also been suggested [30e34]. Hyper-
homocysteinemia is common in PD, and hcy level generally cor-
relates with total LD dose [35,36] even if a genetic contribution
fromMTHRF polymorphism has also been reported [37e39]. In this
context, COMT inhibition may theoretically protect the PNS from
toxic damage. Nonetheless, no evidence supporting such approach
to prevention/treatment of PN in PD was provided so far.
Lower VB12 blood levels in patients with PD and PN compared
to patients with PD only and in high dose versus low dose treat-
ment groups have been consistently reported [35]. Furthermore, LD
daily dose and VB12 levels were shown to be inversely correlated
[35].
Although marked VB12 deﬁciency in PD is uncommon, clinical
improvement after VB12 supplementation was also reported in
C. Comi et al. / Parkinsonism and Related Disorders 20 (2014) 1329e13341332symptomatic patients showing “borderline” VB12 values, suggest-
ing that these patients should be treated, and that more sensitive
indirect methods such as methilmalonic acid (MMA) measurement
should be used [26].
On the other hand, vitamin deﬁciency cannot explain all re-
ported cases of PN: some PN patients had normal VB12 blood
values and a prospective study revealed both a new case of sub-
acute PN and worsening of pre-existing PN in absence of any VB12,
Hcy or MMA change [25]. Accordingly, Lehnerer et al. reported one
case of severe subacute PN developing during continuous LD in-
testinal infusion (CLDII). Since such complication occurred despite
normal VB12 and holotranscobalamin serum levels, authors sug-
gested that PNS damage might be ascribed to accumulation of
neurotoxic metabolites (e.g., MMA and Hcy) [40] (Table 2).
Although VB12 administration may provide beneﬁt in some
cases, supplementation as a preventive treatment is questionable
[28,35,41,42].
Moreover, some patients were shown to display severe subacute
or acute PN, with clinical course and features suggestive of idio-
pathic demyelinating polyneuropathy (Guillain-Barre or CIDP-like
forms), conﬁrmed, in some cases, by the presence of inﬂamma-
tory changes in cerebrospinal ﬂuid and on nerve biopsy [35,43e46]
(Table 2).
Even though co-occurrence of two unrelated conditions can't be
excluded, the increased frequency of severe PN patients treated
with CLDII versus oral LD opens the question whether high LD
bioavailability or the route of administration might subtend this
phenomenon. An hypothetical explanation might involve the trig-
gering of a dysimmune process due to modiﬁcations in the intes-
tinal microenvironment [35].
CLDII is an effective treatment for advanced PD, which is
approved in Europe since 2004. A water-based suspension of LD/
carbidopa in carboximethyl cellulose is administered by intra-
jejunal infusion. This treatment allows to bypass gastric emptying
and improve absorption leading to more stable plasmatic levels
compared to oral LD, andmay therefore provide an improvement of
motor ﬂuctuations and dyskinesia [47]. Patients on CLDII generally
reach higher daily doses compared to oral LD. Furthermore, they
have usually been exposed to oral LD for years. Such features make
these patients at higher risk of developing PN. Indeed, studies
showed higher PN risk in CLDII patients compared to DA patients,
whereas there was no statistically signiﬁcant difference between
CLDII and oral LD patients [25,35]. Nonetheless, Jugel et al. reported
more severe neurographic abnormalities in CLDII compared to oral
LD patients [48] (Table 2). The mechanism underlying PN in oral LD
and CLDII patients is likely to be similar: a correlation between LD
daily dose and PN occurrence has been observed in CLDII patients
too [25,35] (Table 2).
Whilst long term follow-up studies conﬁrmed CLDII efﬁcacy in
controlling motor symptoms, in 2007 the ﬁrst case of acute PN
during CLDII was reported [49] (Table 2).
In the following years, alongwith the increase in CLDII use, there
have been other reports of acute/subacute PN, inconstantly asso-
ciated with signs of encephalopathy [42e46] (Table 2). Some of
these acute conditions were associated with severe weight loss and
low micronutrients blood levels (vitamin B1, B6, B12, and folate)
and improved after CLDII withdrawal with switch back to oral
therapy and vitamin supplementation [35,42,50e52]. Other pa-
tients displayed clinical, neurophysiological and laboratory features
of dysimmune demyelinating PN (Guillain-Barre or CIDP-like
forms). CSF examination showed albuminocytologic dissociation,
and clinical improvement was observed with immunomodulatory
therapy (corticosteroids, plasmapheresis, i.v. immunoglobulins)
[35,46,49,53]. Acute forms appeared weeks/month after CLDII
initiation [35,44e50].Although rare cases of acute PN in patients on high doses of oral
LD were reported, such pattern seems far more frequent in patients
on CLDII [27,44,54] (Table 2).
Acute/subacte PN may be related to different, although poten-
tially overlapping factors: i) Nutritional deﬁciency. Vitamin B deﬁ-
ciency, especially B6, may predispose to acute PN. There are several
cases of acute PN reported in patients who underwent bariatric
surgery [55]. Moreover, an interaction between gel and gastroin-
testinal function cannot be ruled out, and cases of malnutrition
under CLDII were reported. We can speculate that the presence of
gel might interfere with micronutrients absorption. Furthermore
there is a potential interference with microbacterial growth, lead-
ing to malabsorption, as observed during enteral nutrition [56]; ii)
Intestinal ﬂora changes could also facilitate the proliferation of
particular bacterial species (i.e. Campylobacter jejuni) known to
trigger dysimmune reaction [57].4. Open issues and controversies
The main problem in assessing the intrinsic contribution of PD
to PN is that most patients are treated immediately after diagnosis.
Accordingly, available epidemiological data were obtained in small
groups of early PD patients, and no large caseecontrol prospective
study on the prevalence of PN in drug-naïve patients compared to
controls can be performed. On these premises, it will be very
difﬁcult to dissect the role of disease evolution and aging form the
effect of pharmacological treatment.
Studies from the pre-LD era do not indicate signiﬁcant PNS
dysfunction in PD but disease duration was short at that time and
severe motor disability might have masked additional peripheral
symptoms.
Since the discovery of LD in the 1960's, only recent reports have
suggested increased frequency of PN in PD. A review of about 80
clinical trials comparing LD with placebo or other drugs, has been
conducted by Teodoro et al. [58]: no PN cases where reported and
symptoms suggestive of PN showed no signiﬁcant inter-group
difference. Moreover, a comprehensive analysis of pharmacovigi-
lance data did not detect reports of PN associatedwith LD exposure.
Nonetheless, clinical trials population is often not representative of
the whole patient population and follow-up might have been too
short to detect symptoms of PNS dysfunction. Finally, acute/sub-
acute cases might have been under-reported because considered
unrelated to therapy [59].5. Conclusion
The relationship between PD and PNS dysfunction is still un-
certain. There is increasing evidence pointing to a form of small
ﬁber neuropathy intrinsic to PD and therefore not in strict relation
to pharmacological treatment. On the other hand, medium-large
ﬁber PN is also a relatively frequent and potentially severe
complication in advanced LD-treated PD making it difﬁcult to
disentangle disease from treatment-related factors. A possible as-
sociation with subclinical VB12 deﬁciency and hyper-
homocysteinaemia related to LD intake exists andmalnutrition and
vitamin B group deﬁciency would favor acute PN and encepha-
lopathy in CLDII patients.
To further elucidate the above mentioned issues, both early and
advanced PD patients should be more strictly monitored for subtle
neuropathic signs, nutritional and micronutrients status. Prospec-
tive data from cohort studies suggest that neurophysiological
evaluation before CLDII and its periodical assessment during
treatment helps detecting initial symptoms allowing potentially
better management.
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